February 2026
1. BHATTACHARYA R, Kponee-Shovein K, Gao Y, Song Y, et al
   Event-free survival and complete response rate as surrogate endpoints for overall survival in high-risk non-muscle-invasive bladder cancer: A meta-analysis of bacillus Calmette-Guerin-naive or -remote cases.
   Cancer. 2026;132:e70220.
   

   >> Share

   
   December 2025
2. ZHANG L, Liu Z, Ding Y, Sun J, et al
   Natural killer cell infiltration elicits gender-dependent dichotomous clinical outcomes in urothelial carcinoma.
   Cancer. 2025;131:e70196.
   

   >> Share

   
   August 2025
3. APOLO AB, Atiq S, Kydd AR, Chelluri R, et al
   Top advances of the year: Bladder cancer.
   Cancer. 2025;131:e70020.
   

   >> Share

   
   July 2025
4. NIERENGARTEN MB
   FDA approves durvalumab for perioperative immunotherapy for patients with muscle-invasive bladder cancer: In a prespecified analysis, the trial demonstrated a statistically significant improvement in event-free survival and overall survival.
   Cancer. 2025;131:e35912.
   

   >> Share

   
   
5. LAZAROVICH A, Sweis RF
   The current and future role of systemic therapy in non-muscle-invasive bladder cancer.
   Cancer. 2025;131:e35966.
   

   >> Share

   
   January 2025
6. O'DONNELL PH, Loriot Y, Csoszi T, Matsubara N, et al
   Efficacy and safety of pembrolizumab in patients with advanced urothelial carcinoma deemed potentially ineligible for platinum-containing chemotherapy: Post hoc analysis of KEYNOTE-052 and LEAP-011.
   Cancer. 2025;131:e35601.
   

   >> Share

   
   November 2024
7. BERGEROT CD, Schmitz KH, Crane TE, Klaassen Z, et al
   Comprehensive care for patients with bladder cancer: Addressing the interplay of physical, nutritional, and emotional well-being.
   Cancer. 2024 Nov 28. doi: 10.1002/cncr.35670.
   

   >> Share

   
   
8. BRIGGS LG, Parke SC, Beck KL, Sinha D, et al
   Prehabilitative/rehabilitative exercise, nutrition, and psychological support for bladder cancer: A scoping review of randomized clinical trials.
   Cancer. 2024 Nov 2. doi: 10.1002/cncr.35608.
   

   >> Share

   
   October 2024
9. NATHAN KK, Follmer KM, Nash MG, Wolff EM, et al
   The Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer (CISTO) study: Lessons learned about management and patient enrollment in a large, pragmatic, patient-centered trial.
   Cancer. 2024 Oct 14. doi: 10.1002/cncr.35600.
   

   >> Share

   
   September 2024
10. NIERENGARTEN MB
    Promising new treatment shows potential for high-risk bladder cancer.
    Cancer. 2024;130:3075.
    

    >> Share

    
    July 2024
11. NIERENGARTEN MB
    New standard of care for bladder cancer.
    Cancer. 2024;130:2407.
    

    >> Share

    
    
12. MARTINI DJ, Case KB, Gratz D, Pellegrini K, et al
    PD-L1 and nectin-4 expression and genomic characterization of bladder cancer with divergent differentiation.
    Cancer. 2024 Jul 3. doi: 10.1002/cncr.35465.
    

    >> Share

    
    February 2024
13. NIERENGARTEN MB
    Major advancements in first-line treatments for advanced urothelial cancer.
    Cancer. 2024;130:333-334.
    

    >> Share

    
    January 2024
14. PEIPERT JD, Chang J, Li S, di Pietro A, et al
    Reliability, validity, and change thresholds of the NCCN/FACT Bladder Symptom Index (NFBlSI-18) in patients with advanced urothelial cancer.
    Cancer. 2024;130:31-40.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share